| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Apolipoprotein A-I; Apo-AI; ApoA-I; Apolipoprotein A1; Proapolipoprotein A-I; ProapoA-I; Truncated apolipoprotein A-I; Apolipoprotein A-I (1-242); APOA1 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human MUC5B |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-MUC5B antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone AFCO-13; isotype Rabbit IgG; reactivity: Human. Reported application contexts include WB, Flow (as provided in the source record). Boster Bio Anti-MUC5B Monoclonal Antibody catalog # M00719. Tested in WB, Flow Cytometry applications. This antibody reacts with Human.
Key elements and design rationale
- Target: MUC5B (apolipoprotein A1).
- Antibody format: Monoclonal; clone AFCO-13; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
MUC5B (protein: T-cell surface glycoprotein CD4) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility. Reported cellular localization context: Secreted. Tissue expression notes (as provided): Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. The oxidized form at Met-110 and Met-136 is increased in individuals with increased risk for coronary artery disease, such as in carrier of the eNOSa/b genotype and exposure to cigarette smoking. It is also present in increased levels in aortic lesions relative to native ApoA-I and increased levels are seen with increasing severity of disease.
Research relevance and current trends
- Research context keywords from the source record include: Cell Biology,Cytoskeleton/ECM,ECM Proteins,Extracellular Matrix,Signal Transduction.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Flow cytometry: quantify target-positive populations and compare shifts in marker distributions.
Workflow ideas (metafield): Validate MUC5B antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect MUC5B expression by Western blot in cell or tissue lysates, Quantify MUC5B-positive cells by flow cytometry in single-cell suspensions
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 37 kDa; calculated MW: 30778 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 37 kDa
- Cellular localization (provided): Secreted.
- Tissue details (provided): Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. The oxidized form at Met-110 and Met-136 is increased in individuals with increased risk for coronary artery disease, such as in carrier of the eNOSa/b genotype and exposure to cigarette smoking. It is also present in increased levels in aortic lesions relative to native ApoA-I and increased levels are seen with increasing severity of disease.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
